30/11/2019
EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet.
10/10/2019
Read the key recommendations of the EuropaBio Patients BioForum to the new EU institutions.
30/06/2019
25/06/2019
EuropaBio, the voice of the biotech industry, has developed this paper to bring the latest views from the developers and users of genome editing tools and applications.
09/05/2019
Open Letter to Member States on the EU Court Ruling on Mutagenesis.
20/04/2019
Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships.
28/02/2019
EuropaBio invites EU decision-makers to engage with us and our healthcare biotech members who are leading the field in advanced therapies.
20/02/2019
As the Association representing the European biotechnology industry, EuropaBio is fully committed to the development of a legislative environment which facilitates the creation of EU jobs and growth as well as new solutions to healthcare challenges.
19/02/2019
Read about the outcomes of our working policy breakfast in the European Parliament, hosted by MEPs Claudia Gamon and Tomislav Sokol, in cooperation with ARM, the Alliance for Regenerative Medicine.
29/11/2018
As EU court ruling risks blocking innovation, the European biotech industry calls for science-based political decision making on genome edited products.
23/11/2018
Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships.
29/06/2018
A EuropaBio white paper calling for: equal assessment transparency; equal measures for traceability and adverse event reporting; and a level playing field for market access.
28/06/2018
The Pharmaceutical Industry generally welcomes the European Commission’s Proposal for a Regulation on HTA.
28/05/2018
As an association that has manufacturers of both originator and biosimilar medicines as members, EuropaBio strongly doubts that the promises of today’s Commission proposal outweigh the risks of losing investment in new medicines.
31/03/2018
The associations representing the European and British life science industry have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU.
31/03/2018
The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations. With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the EU and UK negotiators to ‘put patients first’ in the negotiations.
28/12/2017
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union.
29/11/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
28/10/2017
The system of IP rewards and incentives exists and works together to allow adequate
time for the companies and investors to recoup their years of investment and fully realise clinical value before their inventions become part of the public domain and can be used by others.
27/09/2017
Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms